Marcum Wealth LLC Boosts Stock Position in Haleon plc (NYSE:HLN)

Marcum Wealth LLC increased its stake in shares of Haleon plc (NYSE:HLN) by 13.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,270 shares of the company’s stock after buying an additional 2,346 shares during the quarter. Marcum Wealth LLC’s holdings in Haleon were worth $167,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pinnacle Bancorp Inc. increased its holdings in shares of Haleon by 29.8% during the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after buying an additional 1,421 shares during the last quarter. Blue Barn Wealth LLC increased its stake in Haleon by 7.3% during the fourth quarter. Blue Barn Wealth LLC now owns 20,858 shares of the company’s stock worth $172,000 after acquiring an additional 1,425 shares during the last quarter. Defined Wealth Management LLC lifted its stake in shares of Haleon by 5.8% in the 1st quarter. Defined Wealth Management LLC now owns 29,009 shares of the company’s stock valued at $246,000 after purchasing an additional 1,590 shares during the last quarter. Confluence Investment Management LLC lifted its stake in shares of Haleon by 2.0% in the 2nd quarter. Confluence Investment Management LLC now owns 83,694 shares of the company’s stock valued at $691,000 after purchasing an additional 1,623 shares during the last quarter. Finally, Essex Financial Services Inc. grew its holdings in shares of Haleon by 13.7% during the 1st quarter. Essex Financial Services Inc. now owns 14,288 shares of the company’s stock worth $121,000 after purchasing an additional 1,727 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Up 0.1 %

Haleon stock traded up $0.01 during trading on Tuesday, reaching $9.52. The stock had a trading volume of 4,897,285 shares, compared to its average volume of 5,246,987. The stock has a market cap of $43.47 billion, a PE ratio of 31.70, a P/E/G ratio of 2.69 and a beta of 0.24. The business has a 50 day moving average price of $8.67 and a 200 day moving average price of $8.44. Haleon plc has a 52-week low of $7.70 and a 52-week high of $9.73. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $3.50 billion for the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a return on equity of 19.85% and a net margin of 9.71%. During the same quarter in the previous year, the firm earned $0.08 EPS. On average, analysts predict that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 19th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, August 16th. Haleon’s payout ratio is 33.33%.

Analysts Set New Price Targets

A number of research analysts have commented on HLN shares. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday. They issued a “buy” rating for the company. Finally, HSBC assumed coverage on Haleon in a report on Wednesday, April 17th. They set a “buy” rating for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.